Molecular NeurobiologyNeurosciencePeer-reviewed journal article
Lack of p62 impairs glycogen aggregation and exacerbates pathology in a mouse model of myoclonic epilepsy of Lafora
Pasquale PellegriniiD, Arnau HerveraiD, Olga Varea, M. Kathryn BreweriD, Iliana López‐SoldadoiD, Anna Guitart-SolanesiD, Mònica AguileraiD, Neus PratsiD, José Antonio del Rı́oiD, Joan Josep GuinovartiD, Jordi DurániD
Abstract
BackgroundLafora disease (LD) is a fatal childhood-onset dementia characterized by the extensive accumulation of glycogen aggregates--the so-called Lafora Bodies (LBs)--in several organs. The accumulation of LBs in the brain underlies the neurological phenotype of the disease. LBs are composed of abnormal glycogen and various associated proteins, including p62, an autophagy adaptor that participates in the aggregation and clearance of misfolded proteins. MethodsTo study the role of p62 in the formation of LBs and its participation in the pathology of LD, we generated a mouse model of the disease (malinKO) lacking p62. ResultsDeletion of p62 prevented LB accumulation in skeletal muscle and cardiac tissue. In the brain, the absence of p62 altered LB morphology and increased susceptibility to epilepsy. ConclusionsThese results demonstrate that p62 participates in the formation of LBs and suggest that the sequestration of abnormal glycogen into LBs is a protective mechanism through which to reduce the deleterious consequences of its accumulation in the brain.
- Citations
- 10
- FWCI
- 1.32
- Field percentile
- top 21%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-cage Behavior
Vaishnav Krishnan, Jun Wu, … Berge Arakel Minassian·The Journal of Comparative NeurologyPeer-reviewed·Jul 1, 2024
- Glial alterations in the glutamatergic and GABAergic signaling pathways in a mouse model of Lafora disease, a severe form of progressive myoclonus epilepsy
Rosa Viana, Teresa Rubio, … Pascual Sanz·bioRxiv·Sep 13, 2024
- Gene replacement therapy for Lafora disease in the Epm2a-/- mouse model
Luis Zafra‐Puerta, Daniel F. Burgos, … José María Serratosa·bioRxiv·Dec 14, 2023
- Deficiency of the E3 Ubiquitin Ligase RBCK1 Causes Diffuse Brain Polyglucosan Accumulation and Neurodegeneration
Mitchell Anthony Sullivan, Felix Nitschké, … Berge Arakel Minassian·bioRxiv·Mar 6, 2018
- Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion
M. K. Brewer, A. Uittenbogaard, … M. Gentry·bioRxiv·Jun 21, 2019
- The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is the major driver of neurodegeneration in synucleinopathies
Anne‐Laure Mahul‐Mellier, Johannes Burtscher, … Hilal Ahmed Lashuel·Proceedings of the National Academy of SciencesPeer-reviewed·Feb 19, 2020